28,098 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Acquired by Tokio Marine Asset Management Co. Ltd.

Tokio Marine Asset Management Co. Ltd. purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 28,098 shares of the company's stock, valued at approximately $9,335,000. Tokio Marine Asset Management Co. Ltd. owned approximately 0.09% of Medpace as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company grew its stake in shares of Medpace by 0.4% in the second quarter. The Manufacturers Life Insurance Company now owns 21,129 shares of the company's stock worth $8,702,000 after acquiring an additional 94 shares in the last quarter. Mackenzie Financial Corp acquired a new stake in Medpace during the 2nd quarter worth $747,000. Northwestern Mutual Wealth Management Co. raised its stake in Medpace by 95.7% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 225 shares of the company's stock valued at $93,000 after acquiring an additional 110 shares during the last quarter. Truist Financial Corp grew its position in Medpace by 21.2% in the 2nd quarter. Truist Financial Corp now owns 3,700 shares of the company's stock valued at $1,524,000 after buying an additional 648 shares during the last quarter. Finally, Cetera Investment Advisers increased its stake in shares of Medpace by 2.3% during the second quarter. Cetera Investment Advisers now owns 11,757 shares of the company's stock worth $4,842,000 after acquiring an additional 263 shares during the period. Hedge funds and other institutional investors own 77.98% of the company's stock.

Medpace Stock Performance

Shares of NASDAQ MEDP traded up $6.31 during midday trading on Wednesday, hitting $353.29. 163,240 shares of the stock traded hands, compared to its average volume of 209,088. Medpace Holdings, Inc. has a one year low of $293.37 and a one year high of $459.77. The firm has a market capitalization of $10.98 billion, a P/E ratio of 30.96, a PEG ratio of 1.79 and a beta of 1.36. The firm has a 50-day moving average of $342.85 and a two-hundred day moving average of $350.27.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. TD Cowen decreased their price target on Medpace from $413.00 to $372.00 and set a "buy" rating on the stock in a research note on Wednesday, October 23rd. Robert W. Baird lifted their price target on shares of Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a research note on Monday, January 27th. Truist Financial reduced their price objective on Medpace from $415.00 to $397.00 and set a "hold" rating for the company in a research report on Monday, October 14th. William Blair restated an "outperform" rating on shares of Medpace in a report on Tuesday, October 22nd. Finally, Baird R W lowered shares of Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $381.44.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.